March 24, 2026 01:51 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Mamata unveils TMC candidate list for Bengal polls; to face Suvendu in Bhabanipur | ‘Not a one-day battle for me’: Mamata Banerjee on facing Suvendu Adhikari in Bhabanipur | Mamata vs Suvendu: Bhabanipur set for high-voltage showdown | Barbaric: India condemns Pakistani airstrike on Kabul hospital | Middle East conflict: Israel says it killed key Iranian commander during overnight strike | Middle East on edge: Kataeb Hezbollah commander Abu Ali al-Askari killed | Middle East on edge: Kataeb Hezbollah commander Abu Ali al-Askari killed | Afghanistan claims Pakistani airstrike on Kabul hospital left 400 killed, Islamabad denies | ECI orders major reshuffle in Bengal police brass a day after poll announcement | 10 patients killed in fire at SCB Medical College Hospital in Cuttack; staff injured
Covid-19 vaccines

Two Covid-19 vaccine candidates await DCGI approval for emergency use in India

| @indiablooms | Jan 03, 2021, at 04:24 pm

New Delhi/IBNS: Two Covid-19 vaccine candidates in India-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-now awaits the approval of the Drugs Controller General of India (DCGI) for emergency use after they have been cleared by the government-appointed panel.

DCGI chief Dr Venugopal G Somani is expected to share details about the vaccine candidates on Sunday.

The government-appointed panel of experts on Saturday cleared the emergency use of indigenous COVID-19 vaccine Covaxin manufactured by Hyderabad-based Bharat Biotech and recommended for approval to the regulator Drugs Controller General of India (DCGI).

The recommendation for the home-grown vaccine came a day after the expert panel cleared Covishield developed by Oxford University and pharma major AstraZeneca to be manufactured by Serum Institute of India (SII).

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) recommended the Drugs Controller General of India (DCGI) to grant permission to Bharat Biotech's Covaxin.

According to reports, the SEC met on Jan 1 and 2 and made the recommendations for the consideration and final decision of DGCI, said the Union Health Ministry.

The Serum Institute of India (SII) is making the vaccine Covishield developed by Oxford University and pharma major AstraZeneca, while Bharat Biotech has partnered with the Indian Council of Medical Research (ICMR) for its indigenous Covaxin.

The final decision to recommend Bharat Biotech's Covaxin came after it presented updated data and justification and request for consideration of their proposal amid cases of mutant Coronavirus strain.

The committee noted that the vaccine has the potential to target mutated coronavirus strains, media reports said.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.